Current Advances and Challenges in CAR-T Therapy for Hematological and Solid Tumors

Area of Science:

• Immunotherapy
• Oncology
• Cellular Therapy

Background:

• Chimeric antigen receptor (CAR) T-cell therapy has transformed hematological malignancy treatment.
• Significant challenges hinder CAR T-cell therapy application in solid tumors.

Purpose of the Study:

• To review the current status of CAR T-cell therapy in hematological malignancies and solid tumors.
• To discuss challenges and future strategies for CAR T-cell therapy.

Main Methods:

• Comprehensive literature search of preclinical and clinical studies.
• Synthesis of data to discuss applications, challenges, and improvements.

Main Results:

• CAR T-cell therapy is effective for certain blood cancers (lymphoma, leukemia, myeloma).
• Solid tumor efficacy is limited by heterogeneity, immunosuppression, and toxicity.
• Advanced CAR designs, combination therapies, and novel manufacturing are key strategies.

Conclusions:

• CAR T-cell therapy has revolutionized some hematological cancer treatments.
• Overcoming hurdles is crucial for extending CAR T-cell therapy to solid tumors.
• Continued research is vital for improving efficacy, safety, and accessibility.